Shares of IDEXX Laboratories Inc. IDXX inched 0.06% higher to $433.28 Friday, on what proved to be an all-around great ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Idexx Laboratories (IDXX – Research Report), with a ...

Idexx Laboratories ( (IDXX) ) has released its Q3 earnings. Here is a breakdown of the information Idexx Laboratories presented to its ...

Idexx Laboratories reported a strong earnings beat for Q3 2024, but reduced its revenue guidance. Idexx Laboratories, a global leader in veterinary diagnostics, focuses on providing a wide range ...

Barclays lowered the firm’s price target on Idexx Laboratories (IDXX) to $481 from $570 and keeps an Overweight rating on the shares. The firm sees the softer visit trends continuing based on ...

Ratings for IDEXX Laboratories IDXX were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of ...

Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth Idexx Laboratories posted a Q3 EPS of $2.79, beating estimates ...

Organic revenue growth supported by benefits from IDEXX execution drivers including continued solid new business gains and double-digit year-over-year global premium installed base growth.

The Animal diagnostic and health care company posted revenue of $975.5 million in the period, which did not meet Street forecasts. Five analysts surveyed by Zacks expected $979.6 million. Idexx ...